|
1
|
Lotan Y, Black PC, Caba L, Chang SS,
Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch
CR, et al: Optimal trial design for studying urinary markers in
bladder cancer: A collaborative review. Eur Urol Oncol. 1:223–230.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Soukup V, Čapoun O, Cohen D, Hernandez V,
Babjuk M, Burger M, Compérat E, Gontero P, Lam T, MacLennan S, et
al: Prognostic performance and reproducibility of the 1973 and
2004/2016 World Health Organization grading classification systems
in non-muscle-invasive bladder cancer: A European Association of
Urology non-muscle invasive bladder cancer guidelines panel
systematic review. Eur Urol Suppl. 72:801–813. 2017. View Article : Google Scholar
|
|
3
|
Westhoff E, Witjes JA, Fleshner NE, Lerner
SP, Shariat SF, Steineck G, Kampman E, Kiemeney LA and Vrieling A:
Body mass index, diet-related factors, and bladder cancer
prognosis: A systematic review and meta-analysis. Bladder Cancer.
4:91–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sethi S, Kong D, Land S, Dyson G, Sakr WA
and Sarkar FH: Comprehensive molecular oncogenomic profiling and
miRNA analysis of prostate cancer. Am J Transl Res. 5:200–211.
2013.PubMed/NCBI
|
|
5
|
Lee JY, Yun SJ, Jeong P, Piao XM, Kim YH,
Kim J, Subramaniyam S, Byun YJ, Kang HW, Seo SP, et al:
Identification of differentially expressed miRNAs and
miRNA-targeted genes in bladder cancer. Oncotarget. 9:27656–27666.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furukawa Y, Kawasoe T, Daigo Y, Nishiwaki
T, Ishiguro H, Takahashi M, Kitayama J and Nakamura Y: Isolation of
a novel human gene, ARHGAP9, encoding a rho-GTPase activating
protein. Biochem Bioph Res Commun. 284:643–649. 2001. View Article : Google Scholar
|
|
7
|
Hall A: Rho GTPases and the control of
cell behaviour. Biochem Soc Trans. 33:891–895. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ang BK, Lim CY, Koh SS, Sivakumar N, Taib
S, Lim KB, Ahmed S, Rajagopal G and Ong SH: ArhGAP9, a novel MAP
kinase docking protein, inhibits Erk and p38 activation through WW
domain binding. J Mol Signal. 2:12007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jaffe AB and Hall A: Rho GTPases in
transformation and metastasis. Adv Cancer Res. 84:57–80. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang T and Ha M: Silencing ARHGAP9
correlates with the risk of breast cancer and inhibits the
proliferation, migration, and invasion of breast cancer. J Cell
Biochem. 119:7747–7756. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Katoh Y and Katoh M: Integrative genomic
analyses on GLI1: Positive regulation of GLI1 by Hedgehog-GLI,
TGFβ-Smads, and RTK-PI3K-AKT signals, and negative regulation of
GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol.
35:187–192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma S, Ksheersagar P and Sharma P:
Diagnosis and treatment of bladder cancer. Am Fam Physician.
80:717–723. 2009.PubMed/NCBI
|
|
15
|
Hall MC, Chang SS, Dalbagni G, Pruthi RS,
Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF: Guideline
for the management of nonmuscle invasive bladder cancer (stages Ta,
T1, and Tis): 2007 update. J Urology. 178:2314–2330. 2007.
View Article : Google Scholar
|
|
16
|
Babjuk M, Böhle A, Burger M, Capoun O,
Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M,
et al: EAU guidelines on non-muscle-invasive urothelial carcinoma
of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Witjes JA, Compérat E, Cowan NC, De Santis
M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A;
European Association of Urology, : EAU guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2013
guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim WT, Kim J, Yan C, Jeong P, Choi SY,
Lee OJ, Chae YB, Yun SJ, Lee SC and Kim WJ: S100A9 and EGFR gene
signatures predict disease progression in muscle invasive bladder
cancer patients after chemotherapy. Ann Oncol. 25:974–979. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bolstad BM, Irizarry RA, Åstrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS,
Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, et al: Predictive value
of progression-related gene classifier in primary non-muscle
invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun J, Nishiyama T, Shimizu K and Kadota
K: TCC: An R package for comparing tag count data with robust
normalization strategies. BMC Bioinformatics. 14:2192013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pignot G, Vieillefond A, Vacher S, Zerbib
M, Debre B, Lidereau R, Amsellem-Ouazana D and Bieche I: Hedgehog
pathway activation in human transitional cell carcinoma of the
bladder. Br J Cancer. 106:1177–1186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee J, Platt KA, Censullo P and Ruiz i
Altaba A: Gli1 is a target of Sonic hedgehog that induces ventral
neural tube development. Development. 124:2537–2552.
1997.PubMed/NCBI
|
|
27
|
Kimura H, Stephen D, Joyner A and Curran
T: Gli1 is important for medulloblastoma formation in Ptc1+/- mice.
Oncogene. 24:4026–4036. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar B, Sinclair J, Khandrika L, Koul S,
Wilson S and Koul HK: Differential effects of MAPKs signaling on
the growth of invasive bladder cancer cells. Int J Oncol.
34:1557–1564. 2009.PubMed/NCBI
|
|
29
|
Spiess PE and Czerniak B: Dual-track
pathway of bladder carcinogenesis: Practical implications. Arch
Pathol Lab Med. 130:844–852. 2006.PubMed/NCBI
|
|
30
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 (Suppl 4):S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC,
Kim IY, Moon SK, Um HD and Choi YH: A four-gene signature predicts
disease progression in muscle invasive bladder cancer. Mol Med.
17:478–485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mari A, Campi R, Tellini R, Gandaglia G,
Albisinni S, Abufaraj M, Hatzichristodoulou G, Montorsi F, van
Velthoven R, Carini M, et al: Patterns and predictors of recurrence
after open radical cystectomy for bladder cancer: A comprehensive
review of the literature. World J Urol. 36:157–170. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yun SJ, Kim SK and Kim WJ: How do we
manage high-grade T1 bladder cancer? Conservative or aggressive
therapy? Investig Clin Urol. 57 (Suppl 1):S44–S51. 2016. View Article : Google Scholar : PubMed/NCBI
|
